Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620282 · ClinicalTrials.gov registry record · Phase 3
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
NCT00620282 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 49 participants.
The verdict
NCT00620282, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone.
Interventions
- DRUG placebo
- DRUG liraglutide
- DRUG glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620282
The ClinicalTrials.gov registry entry for NCT00620282 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00620282 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620282 about?
NCT00620282 is a clinical study titled "The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus". This trial is conducted in the United States of America (USA). The purpose of the trial is to assess the effect of liraglutide on forearm blood flow in subjects with type 2 diabetes who are on diet and lifestyle changes or treated with metformin alone.
What is the current status of trial NCT00620282?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2008-02. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00620282?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG), glimepiride (DRUG).
Who is sponsoring clinical trial NCT00620282?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.